Callan JMB Inc. enters the new week with a striking split between a tightening borrow market and a short position that has been actively cut — a tension worth unpacking for anyone watching this micro-cap logistics name.
The most compelling data point right now is the cost to borrow. At 53.8% APR, borrowing CJMB shares costs more than most equities of any size — and while that rate has eased from a peak of nearly 70% in early April, it remains structurally elevated across the full 30-day window. Despite a 13% decline week-on-week in the borrow rate, there has been no meaningful compression back toward normal levels. When it costs that much to maintain a short, the message from the lending market is that this stock remains genuinely hard to borrow.
Short interest itself, however, tells a different story. Shorts trimmed aggressively mid-week. From around 132,000 shares shorted earlier in April, the position has been cut to roughly 115,700 — a 12.5% reduction in the past week alone. That said, the month-on-month picture is more dramatic in the other direction: short interest more than doubled over the past 30 days, having jumped from under 57,000 shares in early April. Borrow availability has eased slightly from the tightest readings seen in late March and early April, when availability was near its most constrained levels of the past year. At present, availability is running around mid-range relative to those extremes — neither fully loose nor dangerously tight.
The ORTEX short score of 65.7 is meaningfully elevated, placing CJMB in the 8th percentile for short scores across its sector. That score has drifted slightly lower over the past two weeks — it was as high as 68.4 on April 17 — consistent with the partial short covering underway. Days to cover at 2.1 remain modest, limiting squeeze dynamics, but the combination of high borrow costs, elevated float exposure at 2.5% short, and a stock down 11% in the past month keeps the setup charged.
Ownership is unusually concentrated for a Nasdaq-listed name. Founder and CEO Wayne Williams holds 42% of shares outstanding. David Croyle — listed as Chief Medical Officer, an unusual title for an air freight and logistics company — holds another 14%. Both have been net buyers in recent months. Williams purchased shares across multiple sessions in December at prices between $1.65 and $1.79, while Croyle added in early March and again on March 20 at around $1.75. Those buys came at prices well above the current $1.11 close, which is worth noting. The stock has declined roughly 37% from the levels where insiders were most recently accumulating. Net insider buying over the past 90 days totalled 27,000 shares at a combined value of around $46,000 — small in absolute terms, but directionally consistent.
The company made a substantive announcement on April 20, launching what it calls the Atlas Complex — a planned 150-acre campus in Alabama targeting pharmaceutical onshoring, medical logistics and domestic supply chain expansion. The strategic pivot toward nearshoring themes is timely given ongoing supply chain policy shifts. The stock briefly rallied on that news, contributing to the week's 7.8% gain, though it remains well below both the insiders' cost basis and the 30-day average. Earnings history has been volatile: the two most recent events produced one-day moves of +5.6% and +6.9%, while the two before those brought one-day declines of 12.8% and 10.4%.
The next catalyst to watch is whether the Atlas Complex announcement draws institutional attention to the share register, which remains thinly covered by professional investors outside of a handful of small and quant managers.
See the live data behind this article on ORTEX.
Open CJMB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
